Financial Performance - Revenue for the three months ended June 30, 2019, was approximately HK$26,681,000, representing an increase of approximately 21.6% compared to the same period in the previous financial year[9] - Gross profit for the same period was approximately HK$2,055,000, a decrease of approximately HK$159,000 compared to the previous year[9] - Loss attributable to owners of the Company for the three months ended June 30, 2019, was approximately HK$3,106,000, improved from a loss of HK$5,537,000 in the same period of 2018[9] - Total comprehensive loss for the period attributable to owners of the Company was HK$3,138,000, compared to HK$7,356,000 in the previous year[15] - Basic loss per share attributable to owners of the Company was HK0.21 cents, compared to HK0.40 cents in the previous year[16] - The Group reported a loss before tax of HK$3,106,000 for the three months ended June 30, 2019, compared to a loss before tax of HK$5,537,000 for the same period in 2018[24] - The Group's comprehensive loss for the period was approximately HK$3,138,000, including the loss attributable to owners[33] Revenue Breakdown - For the three months ended June 30, 2019, the Group's total revenue was HK$26,681,000, with external sales from the Jewelry Business at HK$21,148,000, Lending Business at HK$71,000, and Pharmaceutical Business at HK$5,462,000[22] - The segment results for the Jewelry Business showed a profit of HK$442,000, while the Lending Business reported a profit of HK$37,000, and the Pharmaceutical Business incurred a loss of HK$42,000, resulting in an overall segment profit of HK$437,000[22] - The Group's revenue from the Jewelry Business increased significantly from HK$9,549,000 in Q2 2018 to HK$21,148,000 in Q2 2019, reflecting a growth of approximately 121%[24] - Revenue from the Pharmaceutical Business decreased by approximately HK$6,512,000 from approximately HK$11,974,000 for the three months ended 30 June 2018 to approximately HK$5,462,000 for the three months ended 30 June 2019, mainly due to changes in government policy regarding the distribution of pharmaceuticals[63] Expenses and Costs - Cost of sales increased from approximately HK$19,730,000 for the three months ended June 30, 2018, to approximately HK$24,626,000 for the three months ended June 30, 2019, consistent with the sales growth[44] - Selling expenses decreased by approximately HK$21,000, from approximately HK$623,000 for the three months ended June 30, 2018, to approximately HK$602,000 for the three months ended June 30, 2019[46] - Administrative expenses decreased by approximately HK$2,432,000, from approximately HK$7,109,000 for the three months ended June 30, 2018, to approximately HK$4,677,000 for the three months ended June 30, 2019[46] - Unallocated expenses for the three months ended June 30, 2019, amounted to HK$3,543,000, contributing to the overall loss before tax[22] Dividends and Shareholder Information - The Board does not recommend the payment of an interim dividend for the three months ended June 30, 2019[9] - The total number of shares issued by the Company as of 30 June 2019 is 1,450,963,725[70] - As of 30 June 2019, Brilliant Chapter Limited holds 822,319,294 shares, representing 56.67% of the Company's issued share capital[67] - Mr. Zhang Chunhua has a personal interest in 1,764,000 shares of the Company, which is 0.12% of the issued share capital[67] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code throughout the review period[108] - The Audit Committee consists of three independent non-executive Directors[110] - The Remuneration Committee is responsible for recommending remuneration policies for all Directors and senior management[110] - The Nomination Committee was established on March 29, 2012, to oversee the nomination and appointment of Directors[115] Future Outlook and Strategy - The Group intends to identify more jewelry wholesaler customers in South China to expand the sales channels of its secondary gold sales agency business[54] - The Group's jewelry retail strategy will focus on mid-end products, supplemented by low-end products, while increasing sales to high-end corporate customers[54] - The Group will periodically review the market situation and profitability of the pharmaceutical and healthcare products business, adjusting business volume according to market demands[64] - The Group plans to strengthen its marketing and channel capabilities to enhance user scale and product quality in the future[65] - The Company is focusing on reallocating resources for more fruitful outcomes in its existing businesses[65] Share Options and Equity - The share option scheme approved on August 5, 2011, allows eligible participants to subscribe for ordinary shares at the highest of the closing price on the offer date, the average closing price for the preceding five trading days, or the nominal value of the shares[75] - The total number of share options granted during the period was 43,400,000, with an exercise price of HK$0.59 per share[87] - The company has a vesting period for share options that varies for each category of participant[95] - The total number of share options lapsed during the period was not specified, but the company had a total of 52,800,000 options outstanding as of June 30, 2019[95]

Financial Performance - The financial year ended March 31, 2019, marked the completion of the annual report for China Brilliant Global Limited and its subsidiaries[12]. - The company reported a significant increase in revenue, with a year-on-year growth of 15%[11]. - The Group's revenue for the year ended 31 March 2019 amounted to approximately HK$84,047,000, representing an increase of approximately 30% from approximately HK$64,739,000 for the year ended 31 March 2018[26]. - The loss before tax for the year was HK$53,994,000, compared to a loss of HK$18,180,000 in the previous year[152]. - The profit attributable to equity holders of the Company for the year was a loss of HK$54,006,000, a significant decline from a profit of HK$23,318,000 in 2018[152]. - Revenue from the Jewelry Business increased by approximately HK$14,953,000 from approximately HK$34,685,000 for the year ended 31 March 2018 to approximately HK$49,638,000 for the year ended 31 March 2019, primarily due to increased trading of gold jewelry products in the PRC[109]. - Revenue from the Pharmaceutical Business increased by approximately HK$6,683,000 from approximately HK$26,635,000 for the year ended 31 March 2018 to approximately HK$33,318,000 for the year ended 31 March 2019, mainly due to increased sales of pharmaceutical products to hospitals[120]. Operational Highlights - User data showed an increase in active users by 20%, reaching a total of 1.2 million users[11]. - New product development initiatives are underway, focusing on enhancing user experience and expanding product offerings[11]. - The company aims to improve operational efficiency by implementing new technologies, expecting a cost reduction of 5%[11]. - The Group continued to diversify its revenue base into jewellery trading and retailing, lending business, and pharmaceutical and healthcare products[26]. - The Group aims to balance business development and financial liquidity to enhance business capacity and performance[20]. - The Group's total staff costs increased to approximately HK$28.5 million for the year ended March 31, 2019, up from HK$9.3 million in 2018, primarily due to the grant of share options[100]. Market Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 15%[11]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 25% increase in market share[11]. - Strategic acquisitions are being considered to bolster the company's competitive position in the market[11]. - The Group plans to allocate more resources to develop its Jewelry Business, particularly in gold jewelry trading, while also controlling selling and administrative expenses to enhance profitability[111]. - The Group aims to strengthen its marketing and channel efforts to increase user base and improve product quality in the future[123]. Financial Position - Total equity increased by approximately HK$34,705,000 to approximately HK$122,555,000 as at 31 March 2019, compared to HK$87,850,000 as at 31 March 2018[32]. - The Group's total cash and cash equivalents amounted to approximately HK$59,573,000 as at 31 March 2019, an increase from HK$10,341,000 as at 31 March 2018, mainly due to the placing of new shares[32]. - The current ratio as of March 31, 2019, was 5.11, compared to 3.03 as of March 31, 2018, indicating improved liquidity[47]. - The Group was in a net cash position as of March 31, 2019, with no significant changes in capital structure during the year[47]. - The Group's total assets and liabilities details are available in the consolidated financial statements, reflecting the financial position as of March 31, 2019[145]. Governance and Leadership - A commitment to corporate governance and sustainability practices was reiterated, aligning with industry standards[11]. - The Board of Directors includes a mix of executive and independent non-executive members, ensuring governance and oversight[186]. - The Company has established service contracts for its directors, with terms ranging from one to three years, subject to re-election at the annual general meeting[193][194][198]. - All independent non-executive directors have confirmed their independence in accordance with GEM Listing Rules[187]. - The company has a strong leadership team with diverse expertise in finance, management, and brand development, enhancing its strategic positioning in the market[126][127][130][131][135][136]. Community and Sustainability - The Company emphasizes the importance of hard-working and dedicated employees as the backbone of its operations[181]. - The Group is committed to contributing to the local community and encourages employees to engage with charities and institutions for sustainable local development[182]. - The Company adheres to non-discriminatory hiring practices and strives to provide a safe and healthy workplace for its employees[181]. - The Group is focused on environmental sustainability and implements measures to reduce waste and conserve resources[178]. - The Group's environmental, social, and governance measures are detailed in the "Environmental, Social and Governance Report" within the annual report[179].

Financial Performance - The Group's revenue for the nine months ended December 31, 2018, was approximately HK$63,727,000, representing an increase of approximately 100.3% compared to the same period of the previous financial year[5]. - The Group's gross profit for the nine months ended December 31, 2018, was approximately HK$4,866,000, a decrease of approximately HK$1,012,000 compared to the same period of the last financial year[5]. - Loss attributable to owners of the Company for the nine months ended December 31, 2018, amounted to approximately HK$13,855,000, compared to a profit of HK$29,852,000 for the same period in 2017[5]. - The Group's loss before tax for the nine months ended December 31, 2018, was HK$13,855,000, compared to a loss of HK$11,924,000 for the same period in 2017[10]. - The company reported a net loss of HK$13,855,000 for the period, compared to a profit of HK$29,852,000 in the previous year[26]. - Total comprehensive expenses for the period amounted to HK$15,837,000, a significant decrease from HK$17,809,000 in the prior year[27]. - The Group's loss for the period from continuing operations for the nine months ended December 31, 2018, was HK$13,855,000, compared to HK$11,929,000 for the same period in 2017[10]. - The basic loss per share from continuing operations for the nine months and three months ended December 31, 2018 was approximately HK$0.0097 and HK$0.0032 respectively, compared to a profit of HK$0.0247 and a loss of HK$0.0033 in the same periods of 2017[128]. Revenue Breakdown - For the nine months ended December 31, 2018, the total revenue was HK$63,727,000, with external sales from the jewellery business at HK$38,555,000, lending business at HK$947,000, and pharmaceutical business at HK$24,225,000[91]. - The revenue from the Jewellery Business increased by approximately HK$19,358,000, from approximately HK$19,197,000 for the nine months ended December 30, 2017, to approximately HK$38,555,000 for the nine months ended December 31, 2018[154]. - The Group's pharmaceutical business revenue rose by approximately HK$14,232,000 from approximately HK$9,993,000 for the nine months ended December 31, 2017, to approximately HK$24,225,000 for the nine months ended December 31, 2018, marking an increase of about 142%[161]. - The revenue from the jewelry business increased from approximately HK$19,197,000 for the nine months ended December 31, 2017, to approximately HK$38,555,000 for the nine months ended December 31, 2018, representing a growth of about 100%[155]. Expenses and Costs - Selling expenses for the nine months ended December 31, 2018, were HK$1,999,000, down from HK$2,744,000 in the previous year[10]. - Administrative expenses for the nine months ended December 31, 2018, were HK$17,179,000, compared to HK$16,171,000 for the same period in 2017[10]. - The cost of sales for the nine months and three months ended December 31, 2018 was approximately HK$58,861,000 and HK$18,043,000 respectively, compared to HK$25,942,000 and HK$6,085,000 in the same periods of 2017[130]. Dividends and Equity - The Board does not recommend the payment of any dividend for the nine months ended December 31, 2018[5]. - As of December 31, 2018, total equity attributable to equity holders of the company was HK$145,096,000[73]. - Total equity as of 31 December 2018 amounted to approximately HK$135,726,000, an increase from HK$87,850,000 as of 31 March 2018[132]. Shareholder Information - Mr. Zhang Chunhua holds 822,319,294 shares, representing 56.67% of the company's issued share capital[166]. - The total number of shares in issue as of December 31, 2018, is 1,450,963,725[169]. - The company granted 18,100,000 shares during the period ending December 31, 2018[187]. Corporate Governance - The company has complied with all provisions of the Corporate Governance Code throughout the review period, except for the appointment of a Chief Executive Officer until May 18, 2018[197]. - The roles of the Chairman and Chief Executive Officer have been separated since May 18, 2018, complying with the Corporate Governance Code[197]. - The Audit Committee, established on March 7, 2000, has reviewed the financial reporting system and internal control procedures of the group[199]. Business Strategy and Operations - The Group intends to focus on mid-end retail products while also increasing sales to high-end corporate customers[153]. - The Group is focusing on strengthening its marketing and channel efforts to increase user base and improve product quality in the future[162]. - The Group plans to expand its jewelry wholesale business by seeking more clients in southern China to broaden sales channels[155].